Zykadia (ceritinib) / Novartis 
Welcome,         Profile    Billing    Logout  
 20 Diseases   18 Trials   18 Trials   1690 News 


«12...891011121314151617181920»
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
    Journal:  Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. (Pubmed Central) -  Nov 11, 2019   
    Furthermore, siRNA-mediated depletion of ALK or IRS2 decreased the phosphorylation of the survival-promoting kinase Akt and of a downstream target, the transcription factor FoxO3, and reduced the viability of three ALK-driven neuroblastoma cell lines. Collectively, our IPP analysis provides insight into the proximal architecture of oncogenic ALK signaling by revealing IRS2 as an adaptor protein that links ALK to neuroblastoma cell survival through the Akt-FoxO3 signaling axis.
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) -  Nov 5, 2019   
    P3,  N=960, Recruiting, 
    The Jab1/CSN5-mediated stabilization of PD-L1 can be efficiently inhibited by Ceritinib in preclinical animal models of ALK+ ALCL. Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Oct 2024 | Initiation date: Mar 2019 --> Oct 2019 | Trial primary completion date: Mar 2022 --> Oct 2022
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Clinical, Journal:  Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review. (Pubmed Central) -  Oct 31, 2019   
    In our case, the cerebral and extra-cranial response obtained with enteral ceritinib intake suggests the proposition of novel inhibitors in these circumstances may take place after first-generation compounds failure or even upfront. Indeed, their grater potency and activity against brain metastases point out the role of their enteral administration in the first-line setting too, when a rapid systemic and intra-cerebral disease response is required.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma (Ballroom Lawn) -  Oct 29, 2019 - Abstract #SNO2019SNO_329;    
    Unbound drug concentrations in brain metastasis and glioblastoma appear insufficient for target modulation. Despite recent reports of clinical response, our findings suggest no role for ceritinib in treating glioblastoma and an unfavorable profile for brain metastases.
  • ||||||||||  Clinical, Review, Journal:  ALK inhibitors, resistance development, clinical trials. (Pubmed Central) -  Oct 18, 2019   
    The inevitable emergence of resistance to alk-directed therapy is central to ongoing research and daily clinical practice for affected patients. In the present review, we highlight the current treatment landscape, the available and emerging clinical trials, and the evolving clinical decision-making in ALK-positive nsclc, with a focus on Canadian practice.
  • ||||||||||  Zykadia (ceritinib) / Novartis, Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Enrollment change, Trial withdrawal:  Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma (clinicaltrials.gov) -  Oct 10, 2019   
    P1/2,  N=0, Withdrawn, 
    Here, we review the role of ALK as a therapeutic target in NSCLC, the testing methods for identifying ALK-rearranged NSCLC, and the various TKIs currently being used or explored for treatment in this setting, with a focus on alectinib from a Chinese perspective. N=30 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  A rare case of large cell neuroendocrine bronchial carcinoma with therapeutic response to ALK inhibitors (A6) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1141;    
    However, TKI sensitivity was generally lower and the disease course more aggressive, including atypical metastatic sites, than in case of ALK + lung adenocarcinoma, despite presence of the relatively favourable EML4-ALK V2 and wild-type TP53. Moreover, TKI efficacy did not correlate with detection of ALK mutations, since second-line alectinib showed the longest duration of response despite unremarkable ALK sequencing results, while later TKI lines did not confer clinical benefit, despite presence of putatively sensitive ALK mutations based on in vitro results.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Phase 0 trial of ceritinib in brain metastases and recurrent glioblastoma (Poster Area (Hall 4)) -  Sep 11, 2019 - Abstract #ESMO2019ESMO_1557;    
    P0
    Unbound drug concentrations achieved in brain metastasis and glioblastoma are unlikely sufficient for target modulation. Clinical trial identification: NCT02605746.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations. (Pubmed Central) -  Sep 11, 2019   
    ...Lipophilic (docusate) salt forms of erlotinib, gefitinib, ceritinib, and cabozantinib (as example smKIs demonstrating low aqueous solubility and high lipophilicity) were prepared and isolated as workable powder solids...Isolation as the lipophilic salt facilitated smKI loading in model lipid formulations at high concentration, increased in vitro solubilization at gastric and intestinal pH and in some cases increased oral absorption (~2-fold for cabozantinib formulations in rats). Application of a lipophilic salt approach can therefore facilitate the use of lipid-based formulations for examples of the smKI compound class where low solubility limits absorption and is a risk factor for increased variability due to food-effects.
  • ||||||||||  Review, Journal:  How I treat ALK-positive non-small cell lung cancer. (Pubmed Central) -  Aug 20, 2019   
    Herein, we attempt to answer these questions through the evidence-based interpretation of studies on ALK-rearranged NSCLC combined with experience gained from our institution. The authors also propose a therapeutic algorithm for the management of this complex and highly treatable disease to assist clinicians globally in the treatment of patients with ALK-positive NSCLC.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Pathology perspective: What are subepithelial lesions? (A2) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_20;    
    In conclusion the diagnosis depends on the layer of the wall. Immunochistochemistry or Molecular Pathology may lead to confusing results if not correlated to the exact site within the wall and the morphology of the lesion.
  • ||||||||||  Alecensa (alectinib) / Roche
    Clinical, Journal:  Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. (Pubmed Central) -  Aug 10, 2019   
    ...Crizotinib was the first ALK inhibitor developed and it demonstrated improved outcomes in patients with ALK-positive advanced NSCLC in comparison with chemotherapy...Because the most frequent mechanism of resistance is the development of a secondary ALK mutation, second (ceritinib, alectinib, brigatinib) and third-generation (lorlatinib) ALK inhibitors were developed...It was also shown to have high intracranial efficacy. In this article, we review clinical trial evidence of alectinib efficacy as well as publications reporting the experience of alectinib in daily practice, with a focus on brain metastases.
  • ||||||||||  cyclophosphamide intravenous / generics
    Journal:  Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. (Pubmed Central) -  Aug 3, 2019   
    These observations suggests that complete and durable response can be safely obtained by using next generation ALK inhibitors in high risk patients ALK+ALCL with CNS relapse or progression. While ALK appears to be a relevant target in RMS in vitro, targeting this kinase in vivo yields no therapeutic efficacy, warranting extreme caution when considering the use of these agents in pediatric RMS patients.
  • ||||||||||  Review, Journal:  Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. (Pubmed Central) -  Aug 1, 2019   
    Canadian recommendations are therefore revised as follows:■ Patients with advanced nonsquamous nsclc have to be tested for the presence of an ALK rearrangement.■ Treatment-naïve patients with ALK-positive disease should initially be offered single-agent alectinib or ceritinib, or both sequentially.■ Crizotinib-refractory patients should be treated with single-agent alectinib or ceritinib, or both sequentially.■ Further treatments could include single-agent brigatinib or lorlatinib, or both sequentially.■ Patients progressing on alk tyrosine kinase inhibitors should be considered for pemetrexed-based chemotherapy.■ Other systemic therapies should be exhausted before immunotherapy is considered. Multiple lines of alk inhibition are now recommended for patients with advanced nsclc with an ALK rearrangement.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer (clinicaltrials.gov) -  Jul 30, 2019   
    P2,  N=0, Withdrawn, 
    N=400 --> 160 N=100 --> 0 | Trial completion date: Dec 2021 --> Jan 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Jan 2019
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma (clinicaltrials.gov) -  Jul 30, 2019   
    P2,  N=33, Active, not recruiting, 
    N=100 --> 0 | Trial completion date: Dec 2021 --> Jan 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Jan 2019 Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2020